Economic evaluation of voriconazole versus amphotericin B in the treatment of invasive aspergilosis;Evaluación económica del uso de voriconazol versus anfotericina B en el tratamiento de la aspergilosis invasiva

Farmacia Hospitalaria

Volumn 29, Issue 1, 2005, Pages 5-10

  Grau Cerrato, Santiago ^a   Mateu De Antonio, J ^a   Soto Alvarez J ^b   Munoz Jareno M A ^b   Salas Sanchez E ^a   Marin Casino M ^a   Rubio Terres C ^c  

^a HOSPITAL DEL MAR   (Spain)

^b PFIZER INC   (United States)

^c HERO Consulting   (Spain)

Author keywords

Amphotericin B; Cost effectiveness analysis; Invasive aspergillosis; Voriconazole

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DRUG COST; DRUG EFFICACY; HOSPITALIZATION; HUMAN; LIVER TOXICITY; MYCOSIS; NEPHROTOXICITY;

EID: 16444367972     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-6343(05)73629-1     Document Type: Article

References (22)

1. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-66.
2. Marcotegui M, Torroba L, Urbiola E, Pérez C, Mateos MC. Aspergilosis invasiva: estudio de 20 casos. Rev Clin Esp 2000; 200: 15-20.
3. Denning DW. Invasive aspergilosis. Clin Infect Dis 1998; 26: 781-805.
4. Terre A, Domingo P, Alonso C, Franquet T, Gurguí M, Vergar G. Aspergilosis pulmonar invasiva: estudio de 33 casos. Med Clin 1998; 110: 421-5.
5. Stevens DA, Kan UL, Judson MA, Morrison VA, Dummer S, Denning DW, et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000; 30: 696-709.
6. Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergilosis. Clin Infect Dis 1999; 29: 1402-7.
7. Gavaldá J, Ruiz I. Recomendaciones para el tratamiento de la infección por Aspergillus spp. Enferm Infecc Microbiol Clin 2003; 21: 571-8.
8. Lumbreras C, Lizasoain M, Aguado JM. Antifúngicos de uso sistémico. Enferm Infecc Microbiol Clin 2003; 21: 366-80.
9. Grau S, Mateu-de Antonio J, Comment: caspofungin acetate for treatment of invasive fungal infections. Ann Pharmacother 2003; 37: 1919.
10. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630-7.
11. Denning DW, Riband P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergilosis. Clin Infect Dis 2002; 34: 563-71.
12. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergilosis. N Engl J Med 2002; 347: 408-15.
13. Gisbert R, Brosa M. Base de datos de costes sanitarios. Version 1.4. Barcelona: Soikos, 2003.
14. Agro KE, Bradley CA, Mittmann N, Iskodjiian M, Ilersich AL, Einerson TR. Sensitivity analysis in health economic and pharmacoeconomic studies. Pharmacoeconomics 1997; 11: 75-88.
15. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001; 33: 1692-6.
16. Kaiser L, Huguenin T, Lew FD, Chapuis B, Pittet D. Invasive aspergillosis. Clinical features of 35 proven cases at a single institution. Medicine 1998; 77: 188-94.
17. Lumbreras C, Vicente C, López-Medrano F. Importancia del tratamiento antifúngico precoz en el tratamiento de la infección fúngica invasora. Enferm Infecc Microbiol Clin 2003; (Supl. 2): 46-56.
18. Costas Lombardia E. Diez años de gasto farmacéutico galopante. Semergen 2001; 27: 348-9.
19. Drummond M. Farmacoeconomía y el farmacéutico del hospital. Farm Hosp 1999; 23: 366-71.
20. Marbaix S, Marciniak A, De Mees V, Aoun M. Cost-effectiveness of voriconazole compared with conventional amphotericin B in first line treatment of invasive aspergilosis in Belgium. Value Health 2003; 6: 750.
21. Calabro AA, Follador W. Cost-effectiveness of voriconazole versus amphotericin B for primary therapy of invasive aspergilosis. Rev Bras Med 2003; 60: 528-35.
22. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.